scholarly journals Polimorfisme COX-1 terhadap Agregasi Platelet pada Pasien Penyakit Jantung Koroner

2021 ◽  
Vol 6 (1) ◽  
pp. 31-35
Author(s):  
Charliandri Saputra Wahab ◽  
J. Nugroho Eko Putranto ◽  
Ike Dhiah Rochmawati

Polimorfisme genetik COX-1 (Cyclooxygenase 1) menjadi salah satu faktor penyebab variasi respon terhadap agregasi platelet. Variasi tersebut dapat menimbulkan Coronary Arthery Disease (CAD) pada pasien penyakit jantung koroner (PJK). Penelitian ini dilakukan di RSUD Sidoarjo di Jawa Timur selama 1 bulan yaitu terhitung mulai bulan November hingga Desember 2017 dengan melibatkan 30 pasien. Metode penelitian yang digunakan yaitu Polymerase Chain Reaction (PCR) agar pemeriksaan polimorfisme COX-1 dan metode Light Transmittance  Aggregometry (LTA) untuk pengukuran agregasi platelet. Dari 30 pasien yang terlibat dengan penelitian ini didapatkan jenis polimorfisme COX-1 homozygout (wild type) sebanyak 4 pasien dengan nilai bp pada kisaran rentang 233-243dan Heterozygot sebanyak 26 pasien dengan kisaran rentang 244-294. Analisis yang dilakukan agar mengetahui hubungan antara polimorfisme COX-1 terhadap agregasi platelet pada pasien PJK yaitu analisis inferensial, dimana diperoleh nilai p=0,423. Dari hasil uji analisis yang diperoleh, maka dapat diambil kesimpulan bahwa tidak hubungan antara polimorfisme COX-1 terhadap agrgasi platelet.

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 2507-2507
Author(s):  
T. Hirose ◽  
K. Nishimura ◽  
K. Fujita ◽  
M. Adachi ◽  
Y. Sasaki ◽  
...  

2507 Background: S-1 is an oral anticancer agent composed of tegafur, CDHP, and potassium oxonate. Tegafur is a prodrug of fluorouracil (5-FU), and CDHP prevents degradation of 5-FU by inhibiting dihydropyrimidine dehydrogenase and enhances the anticancer activity of 5-FU. The biotransformation of tegafur to 5-FU is demonstrated to be catalyzed by CYP2A6. CYP2A6 polymorphisms are seen more frequently in Japanese people than Caucasian. Therefore, we performed a population pharmacokinetic (PPK) analysis of S-1 including the CYP2A6 genotype in Japanese patients with advanced cancer and developed a model describing the disposition kinetics of tegafur, CDHP, and 5-FU after oral administration of S-1. Methods: Fifty-eight patients with advanced cancer were eligible if they had a performance status of 0 to 3 and had adequate organ function. A dose of 80 mg/m2 of S-1 was given orally twice daily for 28 consecutive days, followed by 14 days of rest. The PPK analysis was performed with plasma concentration data for tegafur, CDHP, and 5-FU. The CYP2A6 genotype was analyzed with the polymerase chain reaction-restriction fragment length polymorphism method or an allele-specific polymerase chain reaction-based method. On the basis of the CYP2A6 genotype, all patients were classified into 1 of 3 groups: wild type, 1 variant allele, and 2 variant alleles. Results: Creatinine clearance correlated with the individual clearance of CDHP. Body surface area correlated with the individual clearance and volumes of CDHP and tegafur. In patients with 2 variant alleles of CYP2A6, tegafur clearance was 58% less than that in patients with wild type or 1 variant allele of CYP2A6. In addition, in patients with a history of gastrectomy, the absorption rate constant of tegafur was 66% higher than that in patients with no history of gastrectomy. The time-varying concentration of CDHP was the most appropriate model component describing the inhibitory effect on 5-FU catabolism. The individual Bayesian predictions of CDHP, tegafur, and 5-FU concentrations based on the present PPK model were in good agreement with the observed data. Conclusions: This is the first PPK model of S-1 including the CYP2A6 genotype. No significant financial relationships to disclose.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5178-5178
Author(s):  
Salem H Alshemmari ◽  
Mohmd Edrees ◽  
Marwa Almusailaik

Abstract Abstract 5178 Several somatic mutations have been known to result in an individual to suffer from one or more classes of MPDS. JAK2V617F mutation is the most common somatic mutation that is known as a major contributor to MPDs. Extraction of Total Genomic DNA from Whole Peripheral Blood Blood samples were collected from each subject in vacutainer tubes containing 1.8mg/ml K3-EDTA. Extraction of total genomic DNA was carried following the protocol of a standard QIAGEN DNA Extraction Kit (QIAGEN, USA). Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) for the Detection of JAK2V617FMutation Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR) technique was used in this study to amplify three DNA bands, control (463bp), wild type (229bp), and mutant (279bp) if existent, in which the latter represents cells with JAK2V617F mutation. A 100 ng of DNA template was used for the amplification of the three fragments. HotStart Taq Polymerase Master Mix (Qiagen) was utilized for the amplification JAK2V617FAllele-Specific Real-Time PCR (RT-PCR). Qualitative real-time PCR (RT-PCR) was performed in this study on 100 patients suffering from MPDs, fifty of which were negative and fifty were positive, for the detection of as low as 5% of mutant cells. Standard JAK2 MutaScreen™ Kit (IPSOGEN Cancer Profiler) was used in this procedure, containing JAK2V617F mutant positive control (100%), negative control (0.00%), and a reference sample for the discrimination of negative and very low positive cells. Genomic DNA of MPD samples was diluted in TE buffer (AMBION) to 5.0 ng/μl in concentration. For the amplification of the mutant fragment, TaqMan Universal Master Mix (Applied Biosystems) was added to the mixture of 10x probe/primers and DNA. Polymerase Chain Reaction (PCR) for Direct Sequencing A fragment of 349bp was amplified to include the JAK2 mutational site (V617FG>T) in exon 14. AmpliTaq Gold® PCR Master Mix (Applied Biosystems, USA) was used in this procedure. In this comparative analysis, we diagnosed a total number of 385 MPD patients using three major molecular techniques, direct DNA sequence analysis, ARMS-PCR, and RT-PCR. Out of the 385 patients, 285 were run for DNA sequencing, in which 50 negatives and 50 positives were randomly tested using ARMS-PCR. In comparison, a separate randomized set of 100 (50 negatives & 50 positives) patients that were diagnosed through ARMS-PCR, were also run for RT-PCR for comparative investigation. For the 100 MPD cases that were randomly chosen from the 285 diagnosed set, the 50 positive individuals confirm positivity for JAK2V617F mutation (true positives), whereas 47 were confirmed negative (true negatives) and three patients, in which their somatic cells tested negative using DNA sequencing, were proven positive using ARMS-PCR (false negatives). As shown in Figure (X), well 13–15 display clear 279bp mutant band that represents the presence of JAK2V617F positive cells, whereas the 229bp reflect on the presence of wild type cells. Overall, out of the 100 samples that were run for DNA sequence analysis, misdiagnosis accounts for 3% of the total sample number. On another set of patients, 50 randomly chosen negatives and 50 positives that were assessed using ARMS-PCR were also confirmed for their JAK2V617F somatic mutation through RT-PCR. Results revealed that diagnosis of JAK2V617F mutation utilizing RT-PCR is parallel to the outcome if DNA is tested for positivity using ARMS-PCR. Out of the 100 MPD patients, 50 indicated true negativity, and 50 showed true positivity. Thereby, usage of ARMS-PCR as a diagnostic molecular technique is comparable to RT-PCR. The somatic nature of JAK2V617F mutation has a 3% chance in being misdiagnosed for an MPD when DNA sequencing is implemented over ARMS-PCR based on our results. This is most probably due to the small number of mutant cells that result in a small chromatographic peak on the DNA sequence in response to mutant DNA, hence the false negative diagnosis. Whereas, by utilizing ARMS-PCR as a molecular diagnostic assay, we were able to synthesize mutant DNA of such small number of mutant cells, hence eliminating any chance of misdiagnosis. Intensity of the mutant band displayed on the agarose gel in comparison to the wild type is a reflection of the amount of mutant DNA found in each case. Disclosures: No relevant conflicts of interest to declare.


2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Lequn Kang ◽  
Fei Huang ◽  
Fan Wu ◽  
Qiaoling Zhao

Abstract Lethal fourth-instar larvae ( l- 4 i ) mutant of Bombyx mori , a recently discovered novel mutant, die from energy depletion due to genetic mutation. Beta-glucosidase is a common digestive enzyme that hydrolyzes cellulose in the diet to provide energy. In this study, the mRNA expression profiles of B. mori beta-glucosidase precursor ( BmpreBG ) were characterized by reverse transcription polymerase chain reaction and quantitative real-time polymerase chain reaction. The transcription level of BmpreBG varied in different tissues and developmental stages, except in the pupa and moth, which are the no-diet period. Remarkably, the mRNA expression level of BmpreBG was sharply reduced in l- 4 i but not in the wild type, which suggested that the digestive function of the mutant was severely damaged. This was consistent with the l- 4 i phenotypic traits of not eating mulberries, lack of energy, and ultimate death. 5′-rapid amplification of cDNA ends showed, for the first time, that BmpreBG has a 160-bp 5′-untranslated region. These findings suggested that B. mori β-glucosidase precursor was involved in the death process of l- 4 i mutant larvae.


Sign in / Sign up

Export Citation Format

Share Document